Introduction
Individuals with prediabetes, namely impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), are at increased risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, only 30-40 % of those with IFG/IGT eventually develop T2DM [1] [2] [3] . In fact, about 40 % of individuals who develop T2DM after 10 years have Normal Glucose Tolerance (NGT) at baseline [3] , indicating that the conventional fasting and 2-h oral glucose tolerance test (OGTT) do not recognize most high-risk individuals.
Recently, population-based studies have consistently shown that 1-h post-load glucose (PG) levels may be a better predictor of T2DM and associated complications [4] [5] [6] [7] . Furthermore, NGT individuals with elevated 1-h PG [ 8.6 mmol/l were found to be more insulin resistant, and have worse beta-cell function and an atherogenic profile similar to those with prediabetes [8, 9] . These results were from a research setting using well-defined cohorts. There is sparse information regarding the performance of a 1-h OGTT in a health care setting where the population may be more heterogeneous. Therefore, we investigated the pathophysiological associations of NGT with elevated 1 h ([8.6) glucose levels with dysglycemic conditions in a cohort of outpatients undergoing screening for T2DM.
Methods
This cross-sectional analysis was performed in 236 patients referred to the New York University Langone Diabetes and Endocrine Associates between 2010 and 2015 for T2DM screening due to high HbA1c values (C5.7 %). After an overnight fast, plasma glucose and insulin concentrations were measured fasting, 1-and 2-h after a standard 75-g OGTT. Based on the fasting and 2-h plasma glucose concentrations, subjects were assigned to one of three glycemic categories: (1) NGT: FPG \ 5.6 mmol/l and 2-h glucose \7.8 mmol/l; (2) prediabetes (IFG: C5.6 to \6.9 mmol/l) and/or (IGT) 2-h glucose C7.8 to \11.1 mmol/l; and (3) T2DM (FPG C 7.0 mmol/l and/or 2-h glucose C11.1 mmol/l) [10] . Individuals in the NGT category were further classified based on their 1-h OGTT results as either NGT 1 h-normal (B8.6 mmol/l) or NGT 1 h-high ([8.6 mmol/l).
Other data collected included demographics, body weight, height, and family history of diabetes. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). All biochemical tests (HbA1c, glucose and insulin measurements) were processed in an accredited laboratory (NYU Langone Clinical Laboratory). Wholebody insulin sensitivity was calculated using Matsuda's insulin sensitivity index formula: [10 4 /H(fasting glucose 9 insulin) 9 (mean OGTT glucose 9 mean OGTT insulin)], with mean glucose and insulin calculated from values at fasting, 1 and 2 h of the OGTT [11] . Insulin secretion [12] was estimated from the ratio of the total area under the curve (AUC) for insulin (pmol/l) and for glucose (mmol/l) using the trapezoidal rule (AUC ins/glu ). Beta-cell function was then calculated using the oral disposition index as Matsuda's insulin sensitivity index multiplied by AUC ins/glu [13] . This study was approved by the New York University Langone Medical Center Institutional Review Board.
Statistical analysis
Continuous values were compared across glycemic categories using one-way analysis of variance (ANOVA) with Bonferroni post hoc corrections for normally distributed variables, and Kruskal-Wallis test with Dunn's post hoc corrections for non-normally distributed variables. Polytomous logistic regression was used to determine the association of each glycemic category (NGT 1 h-high , prediabetes and T2DM) compared with NGT 1 h-normal (reference category) for DIo, HOMA-IR, and other covariates. The variables were centered on the mean to estimate the odds ratio (OR) per standard deviation (SD) change. Statistical analysis was performed using SPSS (IBM SPSS Statistics for Windows, version 23.0. Armonk, NY: IBM Corp).
Results
The mean age was 55.7 ± 12.8 years, and 159 (69.1 %) were female. Based on the fasting and 2-h OGTT glucose concentrations, 128 (55.7 %) had NGT, 82 (34.7 %) had prediabetes [IFG: 38 (16.1 %); IGT: 18 (7.6 %), and IFG ? IGT: 26 (11.0 %)], and 20 (8.7 %) had T2DM.
Abnormalities in 1-h PG [ 8.6 mmol/l were observed in individuals with prediabetes (IFG: 60.5 %; IGT 94.4 %; IFG ? IGT: 88.5 %), and T2DM (90.0 %). Overall, patients with prediabetes and T2DM had significantly higher FPG, 1-and 2-h PG concentrations (P \ 0.0001). Among the 128 patients with NGT, those with NGT 1h-high (n = 37) were significantly older (60.3 ± 10.4 years vs. 51.9 ± 12.2; P \ 0.0001) and had higher fasting (5.0 ± 0.4 vs. 4.8 ± 0.4 mmol/l; P = 0.027) and 2-h PG concentrations (6.1 ± 1.1 vs. 5.1 ± 1.1 mmol/l; P \ 0.0001). HbA1c levels were higher in patients with prediabetes (6.2 ± 0.3 %) than those with NGT, regardless of whether they had NGT 1 h-normal (5.9 ± 0.3 %; P \ 0.05) or NGT 1 h-high (5.9 ± 0.3 %; P \ 0.05). However, there were no significant differences in HbA1c levels between the T2DM and other groups (6.0 ± 0.5 %; P [ 0.05).
There was a descending trend in insulin sensitivity and beta-cell function as glycemia worsened. The levels of ISI was 27 % (7.5 vs. 5.5; P = 0.007) and DIo was 12 % (280.3 vs. 247.5; P = 0.001) lowered in individuals with NGT 1 h-high than in those with NGT 1 h-normal . As expected, the levels of DIo and ISI were significantly lower in prediabetic and T2DM compared with NGT-groups (P \ 0.0001). The levels of DIo was further decreased in the T2DM group compared with the prediabetic group (P \ 0.05) (see Fig. 1 ).
Polytomous logistic regression showed a graded association between dysglycemia and DIo [NGT 
Discussion
The results of the present analyses indicate that 1-h PG [ 8.6 mmol/l during an OGTT may provide a useful tool to identify individuals with NGT who are at increased risk of T2DM. Individuals with NGT 1 h-high had reduced insulin sensitivity and beta-cell function compared with NGT 1 h-normal . The levels of ISI were comparable to those with prediabetes, although the latter had worse beta-cell function. These findings were corroborated by other trials using hyperinsulinemic clamp assays [8, 9] . Recently, Fiorentino et al. [14] demonstrated that NGT 1 h-high was a stronger predictor of diabetes than IFG or NGT 1 h-normal and exhibited decreased insulin sensitivity and beta-cell function with the euglycemic hyperinsulinemic clamp method. Our observations are similar using routinely measurable index of beta-cell function. Furthermore, our study cohort was derived from a real-life clinical practice and the analysis also included those with T2DM. The participants recruited in our study were older and not required to have one parent with T2DM as the Eugene Study in the Fiorentino analysis.
Our findings suggest that preventive measures may be more effective in those with subtle abnormalities in betacell function before achieving critical thresholds for IFG or IGT [15] . In accordance with this hypothesis, the US Diabetes Prevention Program demonstrated that lifestyle intervention was significantly greater among individuals with lower glucose concentrations and better beta-cell function at baseline [16] . Furthermore, a recent prevention study among Asian Indians with prediabetes showed that baseline and improvement in beta-cell function are important for regression of prediabetes to NGT [17] . The cross-sectional design and small sample size are limitations of the present study. Our findings provide evidence that 1-h OGTT was able to discriminate those at greater risk of developing T2DM. Prevention studies have focused on prediabetic individuals. Our findings, however, suggest that those with an earlier abnormality, namely an elevated 1-h level, already have compromised beta-cell function and should be identified well before reaching the prediabetic state in the dysglycemia continuum as currently defined by traditional criteria. Because approximately onethird of patients with NGT have 1-h PG [ 8.6 mmol/l, this opens up ''new target subgroup'' to be identified for initiating preventative measures.
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